Your session is about to expire
← Back to Search
Azacitidine for Myeloid Leukemia After Stem Cell Transplant
Study Summary
This trial is testing whether a drug called azacitidine is safe and effective in people who have received a stem cell transplant from a donor.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 730 Patients • NCT03416179Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I had a stem cell transplant and my recovery markers are within the required range.I haven't had chemotherapy, radiotherapy, or experimental treatments in the last 2 weeks.I am a woman who can have children, have a negative pregnancy test, and will use birth control during the study.My brain leukemia is in remission for at least 2 months.I have severe graft versus host disease.I do not have HIV, hepatitis, or cirrhosis.I am between 18 and 75 years old.I have an infection that isn't responding to treatment.I can care for myself but cannot do normal activities or work.My kidney and liver are functioning well, with no chronic hepatitis or cirrhosis.
- Group 1: AZA
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is my profile suitable for enrolment in this research trial?
"This trial is recruiting 43 persons aged 18 to 75, who have been diagnosed with cancer and fulfill the following conditions: AML/MDS/MPN, CMML post Allogeneic SCT experiencing a decrease in total or myeloid chimerism at any time after day 30; ANC> 1000; PLT > 50,000; performance score of 70% by Karnofsky; creatinine clearance higher than 60 ml/min.; total bilirubin <1.5; ALT/AST/Alk Phos < 2.5 x normal without chronic active hepatitis or cirrhosis signs; negative Beta"
Is this exploratory research open to individuals older than 45?
"Candidates eligible for this trial must be aged 18 to 75. In contrast, there are 317 trials available to those below the age of consent and 2363 clinical studies open to participants over 65 years old."
To which medical conditions is azacitidine typically prescribed?
"Azacitidine is usually prescribed for malignant neoplasms, although it can also be employed to address cases of 20-30% blasts, neutropenia and/or thrombocytopenia, as well as anemia."
Have any other investigations been conducted utilizing azacitidine?
"Currently, there are 174 azacitidine clinical trials running with 32 of them being Phase 3. With most studies taking place in Saint Louis, Missouri, the total number of locations trialling this medication is 5671."
Are recruitment efforts still underway for this investigation?
"According to the clinicaltrials.gov, this medical experiment is actively recruiting volunteers. The trial was initially advertised on July 1st 2019 and recently revised December 23rd 2021."
Has the azacitidine molecule received regulatory endorsement from the FDA?
"There is a moderate amount of evidence for azacitidine's safety, so it was allocated a score of 2."
How many participants is the clinical trial currently accommodating?
"Affirmative. Clinicaltrials.gov reveals that the trial, first published on July 1st 2019, is actively recruiting and seeking 43 participants to be enrolled at a single location."
Share this study with friends
Copy Link
Messenger